Additionally, recent research suggests that metformin enhances the physiological effect of GLP-1 by increasing its secretion, and DPP-4 inhibitors also positively impact insulin sensitivity in patients with T2DM. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.